This content is machine translated Type 2 diabetes and cardiovascular disease How to reduce the burden of disease and improve prognosis Type 2 diabetes is known to increase the risk of cardiovascular disease. The ADA guidelines updated in 2025 propose specific screening measures for heart failure, coronary heart disease and PAD....…
View Post 5 min This content is machine translated Type 2 diabetes and CKD: primary and secondary prevention Screening paves the way for the best possible cardiorenal protection The presence of type 2 diabetes is considered a risk factor for the development of chronic kidney disease (CKD). Simple screening measures based on blood and urine samples can detect...…
View Post 6 min This content is machine translated Chronic kidney disease SGLT-2-i: consider for all CKD patients Targeted early detection measures and timely treatment of chronic kidney disease (CKD) are extremely important to halt progression and manage complications. The determination of albuminuria makes it possible to make...…
View Post 5 min This content is machine translated Type 2 diabetes: reduction of microvascular and macrovascular risks The extensive toolbox has a lot to offer The fact that most type 2 diabetics today aim for an HbA1c value of <7% is partly due to the results of the UKPDS. This landmark study showed that the…
View Post 4 min This content is machine translated Type 2 diabetes Patient-oriented and far-sighted treatment A personalized treatment strategy has become an important basic principle in diabetes therapy. In addition to taking into account inter-individual differences in patient characteristics, certain clusters in relation to the…
View Post 5 min This content is machine translated Heart failure and type 2 diabetes SGLT-2-i now recommended for the entire LVEF spectrum Based on data from large clinical trials, it is currently recommended that all patients with diabetes and chronic heart failure – regardless of left ventricular ejection fraction – are treated…
View Post 4 min This content is machine translated SGLT-2-i in type 2 diabetes and CVD Cardioprotective mechanisms of action of empagliflozin – what’s new? Empagliflozin is known to reduce the risk of atherosclerotic cardiovascular disease (CVD) in people with type 2 diabetes and high cardiovascular risk. The mechanisms underlying these effects are not yet…
View Post 5 min This content is machine translated CKD in type 2 diabetes Cardiorenal protection in focus – using modern therapy options Type 2 diabetics can lead a relatively normal life if they adhere to therapy guidelines and maintain HbA1c levels for as many years as possible.are in the target area. Conversely,…
View Post 5 min This content is machine translated KDIGO Guidelines 2022 Modern therapy can slow progression of diabetic nephropathy Diabetes is the most common cause of chronic kidney disease (CKD).The international organization Kidney Disease: Improving Global Outcomes (KDIGO) recently released new guidelines on the management of type 2 diabetes…
View Post 4 min This content is machine translated SUSTAIN-10: Post-hoc analysis Semaglutide and liraglutide in type 2 diabetes: effective and safe with and without SGLT-2-i Based on empirical evidence, professional societies recommend early combination of metformin with an SGLT-2 inhibitor or a GLP-1 receptor agonist in type 2 diabetics. Increasingly, a combined application of the…
